Rosalyn George, MD
Dermatology · Wilmington, NCNPI 1639391931
Payments from drug & device makers
Across 1,335 payments — averaging $4902.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3.9M
- Amgen$767K
- UCB SA$607K
- Eli Lilly$403K
- Janssen Research & Development, LLC$267K
- E.r. Squibb & Sons, L.L.C.$177K
- plus $446K from 29 others
Across 5 payments — averaging $564.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
- Galderma Laboratories, L.p.$1K
- Eli Lilly$224
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 855 | $3,877,596 |
| Amgen | 30 | $766,574 |
| UCB SA | 27 | $606,575 |
| Eli Lilly | 14 | $403,236 |
| Janssen Research & Development, LLC | 56 | $267,274 |
| E.r. Squibb & Sons, L.L.C. | 20 | $177,261 |
| Journey Medical Corporation | 6 | $92,600 |
| Merz North America, Inc. | 22 | $79,275 |
| Regeneron | 16 | $78,800 |
| Vanda Pharmaceuticals Inc. | 14 | $53,413 |
| Pfizer(2 entities) | 41 | $43,614 |
| Dermira, Inc. | 9 | $42,036 |
| Galderma Laboratories, L.p. | 63 | $40,634 |
| UCB, Inc. | 16 | $6,842 |
| Dr.reddy's Laboratories,inc. | 4 | $6,259 |
| Johnson & Johnson | 50 | $801 |
| Novartis | 18 | $337 |
| Regeneron Healthcare Solutions, Inc. | 10 | $240 |
| Lilly USA, LLC | 16 | $226 |
| Almirall LLC | 5 | $216 |
| Sun Pharmaceutical Industries Inc. | 11 | $203 |
| Sanofi | 4 | $182 |
| Revance Therapeutics, Inc. | 1 | $68 |
| Endo Pharmaceuticals Inc. | 1 | $68 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $57 |
| Biofrontera Inc. | 3 | $54 |
| Dermavant Sciences, Inc. | 3 | $49 |
| Organon | 8 | $40 |
| Prugen, Inc. Pharmaceuticals | 3 | $37 |
| Incyte Corporation | 2 | $31 |
| LEO Pharma Inc. | 2 | $28 |
| VYNE Pharmaceuticals Inc. | 1 | $22 |
| EPI Health, LLC | 1 | $21 |
| Arcutis Biotherapeutics, Inc. | 1 | $17 |
| Mayne Pharma Commercial LLC | 1 | $15 |
How this compares
$6,544,701 in reported general payments places this provider in the 95th percentile of 475 dermatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other dermatology in Wilmington
- James AppelWilmington$1.1M
- Aron GewirtzmanWilmington$253K
- Laura TannerWilmington$54K
- Vaishali EscaravageWilmington$37K
- Steven FeldmanWinston Salem$4.3M
- Adnan NasirRaleigh$4.1M
- Christopher SayedChapel Hill$3.3M
- Zoe DraelosHigh Point$3M
- Aida Lugo-SomolinosChapel Hill$2.2M
- Nicole SeminaraHuntersville$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.